Luoxin Pharmaceuticals Group Stock Co Ltd
SZSE:002793
Intrinsic Value
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
Luoxin Pharmaceuticals Group Stock Co Ltd
stock under the Base Case scenario is
4.29
CNY.
Compared to the current market price of 4.21 CNY,
Luoxin Pharmaceuticals Group Stock Co Ltd
is
Undervalued by 2%.
Luoxin Pharmaceuticals Group Stock Co Ltd's market capitalization is 4.6B CNY.
Luoxin Pharmaceuticals Group Stock Co Ltd stock price is 4.21 CNY.
Luoxin Pharmaceuticals Group Stock Co Ltd stock price (4.21 CNY) is 2% less than its Intrinsic Value (4.29 CNY).
Luoxin Pharmaceuticals Group Stock Co Ltd stock price (4.21 CNY) is 27% less than its DCF Value (5.74 CNY). Open DCF Valuation
Luoxin Pharmaceuticals Group Stock Co Ltd stock (2.85 CNY) is 32% less than its price (4.21 CNY). Open Relative Valuation
Luoxin Pharmaceuticals Group Stock Co Ltd.
Luoxin Pharmaceuticals Group Stock Co Ltd has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (971m CNY).
Luoxin Pharmaceuticals Group Stock Co Ltd's short-term assets (3B CNY) exceed its short-term liabilties (2B CNY).
Luoxin Pharmaceuticals Group Stock Co Ltd's Revenue has dropped by 68% over the past 12 months.
Luoxin Pharmaceuticals Group Stock Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 9% to -28%.
Luoxin Pharmaceuticals Group Stock Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 8% to -19%.
Luoxin Pharmaceuticals Group Stock Co Ltd has positive Gross Profit for the last twelve months.
Luoxin Pharmaceuticals Group Stock Co Ltd's long-term assets (6B CNY) exceed its long-term liabilties (3B CNY).
Luoxin Pharmaceuticals Group Stock Co Ltd has negative three-year average ROIC (Return on Invested Capital): -2%. The company is not efficient at using invested capital to generate operating income.
Luoxin Pharmaceuticals Group Stock Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -19%.
Luoxin Pharmaceuticals Group Stock Co Ltd has negative Operating Income for the last twelve months.
Luoxin Pharmaceuticals Group Stock Co Ltd has negative Net Income for the last twelve months.
Luoxin Pharmaceuticals Group Stock Co Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -28%.
Luoxin Pharmaceuticals Group Stock Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.51.
Luoxin Pharmaceuticals Group Stock Co Ltd has negative three-year average ROE (Return on Equity): -5%. The company is not efficient at transforming stockholders' equity into net income.
Luoxin Pharmaceuticals Group Stock Co Ltd has positive Free Cash Flow for the last twelve months.
Luoxin Pharmaceuticals Group Stock Co Ltd's Revenue has been falling by 36% per year for the last 3 years.
Luoxin Pharmaceuticals Group Stock Co Ltd's Altman Z-Score is very low and is equal to 1.21.
Valuation Backtest
Luoxin Pharmaceuticals Group Stock Co Ltd
Run backtest to discover the historical profit from buying and selling
Luoxin Pharmaceuticals Group Stock Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Luoxin Pharmaceuticals Group Stock Co Ltd
Balance Sheet Decomposition
Luoxin Pharmaceuticals Group Stock Co Ltd
| Current Assets | 2.5B |
| Cash & Short-Term Investments | 971m |
| Receivables | 821.4m |
| Other Current Assets | 734.8m |
| Non-Current Assets | 3.3B |
| Long-Term Investments | 232.6m |
| PP&E | 1.7B |
| Intangibles | 686m |
| Other Non-Current Assets | 703m |
| Current Liabilities | 2B |
| Accounts Payable | 393.6m |
| Accrued Liabilities | 67.3m |
| Short-Term Debt | 888.7m |
| Other Current Liabilities | 695.1m |
| Non-Current Liabilities | 863.5m |
| Long-Term Debt | 607.1m |
| Other Non-Current Liabilities | 256.4m |
Earnings Waterfall
Luoxin Pharmaceuticals Group Stock Co Ltd
|
Revenue
|
1.6B
CNY
|
|
Cost of Revenue
|
-1.4B
CNY
|
|
Gross Profit
|
239.1m
CNY
|
|
Operating Expenses
|
-1.5B
CNY
|
|
Operating Income
|
-1.3B
CNY
|
|
Other Expenses
|
325.6m
CNY
|
|
Net Income
|
-957.7m
CNY
|
Free Cash Flow Analysis
Luoxin Pharmaceuticals Group Stock Co Ltd
Profitability Score
Profitability Due Diligence
Luoxin Pharmaceuticals Group Stock Co Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Luoxin Pharmaceuticals Group Stock Co Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Luoxin Pharmaceuticals Group Stock Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Luoxin Pharmaceuticals Group Stock Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Luoxin Pharmaceuticals Group Stock Co Ltd
Shareholder Return
Price
Luoxin Pharmaceuticals Group Stock Co Ltd
| Average Annual Return | 7.48% |
| Standard Deviation of Annual Returns | 50.49% |
| Max Drawdown | -80% |
| Market Capitalization | 4.6B CNY |
| Shares Outstanding | 1 087 588 486 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Luoxin Pharmaceuticals Group Stock Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 6,393 full-time employees. The company went IPO on 2016-04-15. The firm operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The firm conducts its businesses in the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Luoxin Pharmaceuticals Group Stock Co Ltd
stock under the Base Case scenario is
4.29
CNY.
Compared to the current market price of 4.21 CNY,
Luoxin Pharmaceuticals Group Stock Co Ltd
is
Undervalued by 2%.
You don't have any saved screeners yet
